Best HRT Providers in 2026 — Ranked & Reviewed
Hormone replacement therapy — primarily estrogen, paired with progesterone for women who have a uterus — is well-supported care for many women navigating perimenopause and menopause, easing hot flashes, night sweats, sleep disruption, and other symptoms tied to declining estrogen. We ranked HRT telehealth providers on whether dosing and delivery route (patch, gel, spray, or pill) are individualized rather than templated, whether progesterone is included for the women who need it, the honesty of 'bioidentical' marketing claims, and ongoing monitoring rather than a single set-and-forget prescription.
Lowest verified price: $39/mo2 providers compared
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
2 hrt providers compared · independently scored against our six-factor methodology.
Compare the top providers at a glance
Logos, our editorial rating, price, medications, and coverage — the fastest way to narrow the list.
- ★ Editor's PickFrom /mo$39Coverage36 statesMedicationsProgesteroneEstrogen
- Best Budget
physician-supervised bioidentical estradiol vaginal cream by subscription
From /mo$83CoverageCheck intakeMedicationsEstrogen
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
★ Editor's Pick | $39 | ProgesteroneEstrogen | 36 states | Visit → | |
Best Budget physician-supervised bioidentical estradiol vaginal cream by subscription | $83 | Estrogen | Check intake | Visit → |
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
Detailed Reviews
Winona
Verified partnerWinona is a DTC telehealth provider offering bioidentical hormone replacement therapy for perimenopausal and menopausal women, with a symptom-based intake and no mandatory hormone testing — prescriptions are filled by Winona-operated 503A compounding pharmacies and shipped home. The catalog spans nine formulations across creams, pills, and patches, from $39/month to a $149/month estrogen patch. Available in 36 states; testosterone is not offered.
Score Breakdown
Inner Balance
Verified partnerBest for: physician-supervised bioidentical estradiol vaginal cream by subscription
Inner Balance is a women-focused bioidentical hormone replacement (BHRT) telehealth brand founded in 2023 by Dr. Sarah Daccarett, MD, and headquartered in Boise, Idaho. Its flagship is Oestra, a topical bioidentical estradiol cream for perimenopause, menopause, PCOS, and postpartum symptoms, with no baseline labs required to start. Pricing is a flat $199/mo for the first six months, then $99.50/mo ongoing, with a six-month satisfaction guarantee.
Score Breakdown
Pros
- ✓Founder Dr. Sarah Daccarett, MD is named publicly — a board-certified hormone and longevity specialist
- ✓Flat subscription ($199/mo first 6 months, then $99.50/mo) is itemized and predictable
- ✓No baseline lab work required to start — less friction than TRT/HRT peers
- ✓Six-month satisfaction guarantee — uncommon in compounded BHRT telehealth
- ✓LegitScript verification badge displayed
- ✓Fulfilled via an FDA-registered 503B compounding pharmacy
- ✓Founded 2023 in Boise, ID with a clear focus on women dismissed in traditional primary care
Cons
- ✗Outside WLR's GLP-1 / weight-loss scope — women researching weight-loss medication should use one of the GLP-1 providers here
- ✗States served not listed — you can't confirm pre-purchase whether your state is covered
- ✗Compounded BHRT (Oestra) is not FDA-approved as a finished product and is not reviewed for safety, efficacy, or quality
- ✗Legal entity name, HQ address beyond "Boise, ID," and 503B pharmacy partner not disclosed
- ✗No BBB profile, PCAB badge, or Trustpilot score located — LegitScript is the only trust signal found
- ✗Six-month minimum is a higher upfront spend ($1,194) than $99/mo-from-day-one peers
- ✗Founded 2023 — a young brand with limited independent outcome data
How to choose an HRT provider
Hormone replacement therapy — primarily estrogen, often paired with progesterone — is legitimate, evidence-supported care for many women in perimenopause and menopause. Dosing and delivery route should be individualized, not templated, and monitoring shouldn't stop at the first prescription.
What to look for
- Individualized dosing and delivery route. Estrogen comes as a patch, gel, spray, or pill, each with a different risk/benefit profile (transdermal routes avoid the first-pass liver effect that oral estrogen carries). A good provider discusses the trade-offs rather than defaulting everyone to the same product.
- Progesterone included when you have a uterus. Women with a uterus who take estrogen need a progestogen alongside it to protect the endometrium from unopposed estrogen stimulation. A provider prescribing estrogen alone without asking about hysterectomy status is skipping a basic safety check.
- Ongoing monitoring, not a one-time prescription. Follow-up should reassess symptoms, side effects, and — depending on your history — periodic screening. A platform that auto-renews the same prescription indefinitely with no check-in is not providing real clinical oversight.
Red flags to avoid
- Estrogen with no progesterone plan (and you have a uterus). Unopposed estrogen in a woman with an intact uterus raises endometrial risk. If the intake doesn't ask about hysterectomy status before prescribing estrogen alone, that's a real gap.
- "Bioidentical" marketed as inherently safer with no basis. FDA-approved bioidentical estradiol and progesterone exist and are well-studied; custom-compounded "bioidentical" blends marketed as safer or more natural than FDA-approved options are a marketing claim, not an evidence-based one.
- No baseline workup or ongoing check-ins. A provider that prescribes HRT with no discussion of your personal or family history (breast cancer, clotting disorders, cardiovascular disease) and no scheduled follow-up is skipping the individualization that makes HRT appropriate for you specifically.
- No path to an in-person visit for new or unusual symptoms. Telehealth is reasonable for routine HRT management, but breakthrough bleeding, new breast findings, or leg swelling need an in-person evaluation. A platform with no escalation path is a gap, not a convenience.
Every provider ranked above is scored against these criteria across our six-dimension methodology, and prices are re-verified against each provider’s live site.
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Frequently Asked Questions
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.